Michele Prisciandaro

10PUBLICATIONS
97CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersLiquid biopsiesClinical nutrition
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 12, 2024
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio

|May 10, 2024
Outcomes of chemotherapy/chemoradiation vs. R2 surgical debulking vs. palliative care in nonresectable locally recurrent rectal cancer.

Luca Sorrentino, Andrea Scardino, Luigi Battaglia

|Aug 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.

Giovanni Randon, Yoshiaki Nakamura, Rona Yaeger

|May 02, 2023
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.

Annalisa Petrelli, Sabrina Rizzolio, Filippo Pietrantonio

|Nov 10, 2022
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases.

Federica Marmorino, Michele Prisciandaro, Mirella Giordano

|Jul 02, 2021
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.

Alessandra Raimondi, Federica Palermo, Michele Prisciandaro

Pageof 2

Frequent Collaborators

7 joint publications

Filippo Pietrantonio

3 joint publications

Sara Lonardi

3 joint publications

Chiara Cremolini

3 joint publications

Andrea Sartore-Bianchi